The logo and ticker for Eli Lilly and Co. are displayed on a screen on the floor of the New York Stock Exchange (NYSE) in New York, U.S., May 18, 2018. REUTERS/Brendan McDermid/File Photo
(Reuters) – Eli Lilly and Co will target cancer drug developers for deals, Chief Executive Officer Dave Ricks said on a post-earnings conference call on Wednesday.
“Probably because of the number of opportunities, you will see us active in oncology – that’s where a lot of early stage biotech is,” Ricks said.
Reporting by Manas Mishra in Bengaluru; Editing by Sriraj Kalluvila
Our Standards:The Thomson Reuters Trust Principles.
